Core A: Administration The Administrative Core A (Admin Core) provides the administrative framework to support the four Projects and the other Core of this PPG. Its main focus is to allow the PPG investigators to dedicate their efforts on scientific advances to fulfill the goals of this PPG. The Core is led by Antoni Ribas, M.D. with the Core Co- lnvestigator David Gjertson, Ph.D., the senior PPG biostatistician. With this resubmission Core A incorporates a new service, bioinformatics support, which is a common need for the four Projects to allow adequate interpretation of high throughput data and the ability to use advanced algorithms for its analysis This will be provided by Stan Nelson, M.D. and Tom Graeber, Ph.D. It is supported by a staff biostatistician, a regulatory coordinator, an administrative and a fund manager, and a clinical trials coordinator and data manager. The Core has two specific Aims.
Aim 1 is focused on fostering the scientific aspects of the PPG providing oversight of meeting the milestones and objectives for each Project and Core. This will be facilitated by a series of in-process and formal evaluation meetings with the oversight of the Internal Advisory Board (lAB) made up by four senior Investigators at UCLA and Caltech, James Economou, M.D., Ph.D., James Heath, Ph.D. (Caltech), Owen Witte, M.D., and Hong Wu, Ph.D. This oversight and scientific support is extended by the engagement of three External Expert Consultants (EEC). Boris Bastian, M.D., Ph.D. (UCSF), Charles Sawyers, M.D. (MSKCC) and Cassian Yee (Fred Hutch).
Aim 2 is focused on providing the appropriate administrative and fiscal support for the daily activities within PPG. This includes administrative and coordination support, facilitating data and resource sharing plans, clinical trial and biospecimen regulatory, study coordination and data management.
The Admin Core will support all Projects and Cores to allow them to focus the efforts on the proposed scientific plans. As such, it is an integral part of the PPG scientific goals and provides Its relevance for the proposed patient-oriented research.
|Atefi, Mohammad; Avramis, Earl; Lassen, Amanda et al. (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446-57|
|Mok, Stephen; Koya, Richard C; Tsui, Christopher et al. (2014) Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 74:153-61|
|Zimman, Alejandro; Titz, Bjoern; Komisopoulou, Evangelia et al. (2014) Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin. PLoS One 9:e84488|
|Lin, Millicent; Chen, Jie-Fu; Lu, Yi-Tsung et al. (2014) Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res 47:2941-50|
|Shi, Hubing; Hong, Aayoung; Kong, Xiangju et al. (2014) A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 4:69-79|
|Thai, Minh; Graham, Nicholas A; Braas, Daniel et al. (2014) Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab 19:694-701|
|Senese, S; Lo, Y C; Huang, D et al. (2014) Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis 5:e1462|
|Graham, Nicholas A; Graeber, Thomas G (2014) Complexity of metastasis-associated SDF-1 ligand signaling in breast cancer stem cells. Proc Natl Acad Sci U S A 111:7503-4|
|Shi, Hubing; Hugo, Willy; Kong, Xiangju et al. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93|
|Tumeh, Paul C; Harview, Christina L; Yearley, Jennifer H et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-71|
Showing the most recent 10 out of 20 publications